{"schema":"hottub-news/prospects/v1","item":{"id":"n_khg5uqj2dki7izx7wtyq","title":"FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer","title_en":null,"url":"https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-64cu-sar-bispsma-for-psma-pet-in-biochemically","outlet":"OncLive","published":"2026-11-12T15:52:00Z","sponsored":false,"page":"https://hottub.news/articles/n_khg5uqj2dki7izx7wtyq"},"prospects":[{"name":"OncLive","kind":"organization","role":"outlet","website":"https://onclive.com/","entity":"wikidata:Q140944690","source":"https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-64cu-sar-bispsma-for-psma-pet-in-biochemically","note":"Published: FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer (2026-11-12)","reason":"Published “FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer” on 2026-11-12","group":"Outlet","add_url":"https://crm.joinhottub.com/relationships/add#name=OncLive&kind=organization&website=https%3A%2F%2Fonclive.com%2F&source=https%3A%2F%2Fwww.onclive.com%2Fview%2Ffda-grants-breakthrough-therapy-designation-to-64cu-sar-bispsma-for-psma-pet-in-biochemically&entity=wikidata%3AQ140944690&note=Published%3A%20FDA%20Grants%20Breakthrough%20Therapy%20Designation%20to%2064Cu-SAR-bisPSMA%20for%20PSMA%20PET%20in%20Biochemically%20Recurrent%20Prostate%20Cancer%20%282026-11-12%29","propose":{"name":"OncLive","kind":"organization","reason":"Published “FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer” on 2026-11-12","requestId":"news:n_khg5uqj2dki7izx7wtyq:wikidata:Q140944690:3920aadf","website":"https://onclive.com/","sourceUrl":"https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-64cu-sar-bispsma-for-psma-pet-in-biochemically","entity":"wikidata:Q140944690"}}],"someone_else":{"source":"https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-64cu-sar-bispsma-for-psma-pet-in-biochemically","note":"In the news: FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer (OncLive, 2026-11-12)"},"crm":{"name":"CRM by Hottub","add":"Open add_url in a browser: CRM by Hottub's add form, filled in. Nothing is saved until the person presses Add.","mcp":"https://crm.joinhottub.com/api/crm/mcp","tool":"propose_relationship","propose":"If you're connected to CRM by Hottub's MCP server with proposal access, call propose_relationship with `propose` as its arguments. An owner approves it before anything is added. Keep the arguments as given: retries reuse requestId."}}